26
14
1
カタログ番号 | 製品名 | 別名 | ターゲット |
---|---|---|---|
T39957 | CDK4/6-IN-6 | CDK | |
CDK4/6-IN-6 is a potent CDK4/CDK6 inhibitor with Ki of 0.6 nM and 13.9 nM for CDK4/Cyclin D1 and CDK6/Cyclin D3, respectively. | |||
T10736 | CDK4/6-IN-2 | CDK | |
CDK4/6-IN-2 is a potent CDK4 and CDK6 inhibitor (IC50s: 2.7 and 16 nM). | |||
T39956 | CDK4/6-IN-5 | CDK4/6-IN-5 | |
CDK4/6-IN-5 is a highly effective inhibitor of CDK4 and CDK6, with Ki values of 0.2 and 4.4 nM for CDK4/Cyclin D1 and CDK6/Cyclin D3, respectively (WO2019207463A1, example A93). | |||
T10737 | CDK4/6-IN-3 | CDK | |
CDK4/6-IN-3 is a brain-penetrant CDK4/CDK6 inhibitor (Kis: <0.3 nM and 2.2 nM) used for the treatment of glioblastoma. It inhibits CDK1 with a Ki of 110 nM. | |||
T10738 | Abemaciclib metabolite M20 | CDK4/6-IN-4,LSN3106726 | CDK |
Abemaciclib metabolite M20 (CDK4/6-IN-4) is an active metabolite of Abemaciclib. Abemaciclib metabolite M20 is a selective CDK4/6 inhibitor and can be used for researches on the treatment of cancer. | |||
T67780 | AM5992 | CDK4/6-IN-16 | CDK |
AM5992 (example 195) is a potent CDK4 and CDK6 inhibitor (CDK4, IC50= 0.013 μM). AM5992 can be used for the research of CDK4-mediated disorders. | |||
T60328 | CDK4/6-IN-12 | ||
CDK4/6-IN-12 is a potent cyclin-dependent kinase 4/6 (CDK4/6) inhibitor. CDK4/6-IN-12 has enzymatic inhibitory activity against CDK4 and CDK6 with IC 50 of 592.3 nM and 3090 nM, respectively. CDK4/6-IN-12 can be used in ... | |||
T72928 | CDK4/6-IN-15 | ||
CDK4/6-IN-15, an orally active and selective inhibitor of CDK4/6, effectively halts the growth of cancer cells by arresting the cell cycle at the G1 phase and inhibiting the phosphorylation of the retinoblastoma tumor su... | |||
T62605 | CDK4/6-IN-13 | ||
Compounds 10B and 10C, functioning as cdk4/6 inhibitors, demonstrated low nanomolar activity, optimal antiproliferative effects, excellent metabolic properties, and acceptable pharmacokinetics targeting cdk4/6. | |||
T62192 | CDK4/6-IN-9 | ||
CDK4/6-IN-9 (compound 10) is a selective inhibitor of CDK4/6, capable of acting on CDK6/cyclin D1 (IC50: 905 nM). CDK4/6-IN-9 has potential research value in multiple myeloma (MM). | |||
T79112 | CDK4/6-IN-17 | CDK | |
CDK4/6-IN-17 (compound 12) is an orally bioavailable inhibitor of CDK4/6, demonstrating potent activity with IC50 values between 10-100 nM in BE(2) cells. It has shown efficacy in inhibiting tumor growth in the COLO205 x... | |||
T61892 | CDK4/6-IN-8 | ||
CDK4/6-IN-8 (Compound 7p) is a selective inhibitor of CDK4 (IC50=5.01 nM) and CDK6 (IC50=3.97 nM). | |||
T61738 | CDK4/6-IN-7 | ||
CDK4/6-IN-7, a highly potent and selective orally active inhibitor of CDK4/6, demonstrates impressive inhibition activity with IC50 values of 1.58 nM and 4.09 nM respectively. This compound is particularly valuable for b... | |||
T74370 | CDK4/6-IN-11 | ||
CDK4/6-IN-11 is a potent PROTAC CDK4/6 degrader. | |||
T64244 | CDK4/6-IN-10 | ||
CDK4/6-IN-10 is a selective, potent, orally active inhibitor of CDK4 (IC50: 22 nM) and CDK6 (IC50: 10 nM) with antitumour effects. CDK4/6-IN-10 has potential for studies in multiple myeloma (MM). | |||
T72951 | CDK4/6-IN-14 | ||
CDK4/6-IN-14 is a potent, highly selective inhibitor of Cyclin-Dependent Kinases 4 and 6 (CDK4/6), demonstrating inhibition concentrations (IC50s) of 10 nM and 16 nM, respectively. It possesses over 60-fold greater selec... | |||
T36694 | XY028-140 | XY028-140 | CDK , Ligand for E3 Ligase |
XY028-140 is a selective CDK4/CDK6 degrade and inhibits both CDK4/6 expression and activity in cancer cells. XY028-140 is a PROTAC connected by ligands for Cereblon and CDK. | |||
T21720 | GP-82996 | Cdk4/6 Inhibitor IV,CINK4 | CDK |
GP-82996 (CINK4) is a pharmacological inhibitor specifically targeting CDK4/6, exhibiting IC50 values of 1.5 μM for CDK4/cyclin D1, 5.6 μM for CDK6/cyclin D1, and 25 μM for Cdk5/p35. It effectively induces apoptosis in U... | |||
T75029 | HEMTAC CDK4/6 degrader 1 | ||
HEMTAC CDK4/6 degrader 1 is a PROTAC connected by ligands for HSP90 and CDK4/6 with a K d value of 35.7 μM. HEMTAC CDK4/6 degrader 1 induces CDK4/6 degradation in B16F10 melanoma cells. HEMTAC CDK4/6 degrader 1 arrests c... | |||
T75127 | CDK-IN-12 | ||
CDK-IN-12 (Example 20), a CDK inhibitor, effectively inhibits CDK4/6, demonstrating IC50 values below 20 nM [1]. | |||
T36967 | LSN3106729 hydrochloride | ||
LSN3106729 hydrochloride, the metabolite of Abemaciclib , is a CDK inhibitor with antitumor activity. LSN3106729 hydrochloride and a CRBN ligand have been used to design PROTAC CDK4/6 degrader[1]. [1]. Edward S. Kim, et ... | |||
T35476 | BSJ-04-132 | ||
Selective Cdk4 degrader. Degrades Cdk4 in Molt-4 cells, with no effect on Cdk6 levels. Displays cereblon-dependent degradation. Jiang et al (2019) Development of dual and selective degraders of cyclin-dependent kinases 4... | |||
T63199 | Dalpiciclib hydrochloride | ||
Dalpiciclib (SHR-6390) hydrochloride is a highly selective, orally active CDK4/6 inhibitor with IC50 values of 12.4 nM and 9.9 nM, respectively, and is capable of acting as an antitumor agent in breast and esophageal squ... | |||
T79572 | MAPK-IN-2 | EGFR | |
MAPK-IN-2 (compound 3h) is an efficacious MAPK inhibitor with antineoplastic properties that significantly hinders proliferation across various cancer cell lines. It demonstrates robust suppression of the MAPK pathway (E... | |||
T69196 | AG-012986 | ||
AG-012986 is a multitargeted cyclin-dependent kinase (CDK) inhibitor active against CDK1, CDK2, CDK4/6, CDK5, and CDK9, with selectivity over a diverse panel of non-CDK kinases. AG-012986 showed antiproliferative activit... | |||
T69197 | AG-012986 HCl | ||
AG-012986 HCl is a multitargeted cyclin-dependent kinase (CDK) inhibitor active against CDK1, CDK2, CDK4/6, CDK5, and CDK9, with selectivity over a diverse panel of non-CDK kinases. AG-012986 HCl showed antiproliferative... |
カタログ番号 | 製品名 | Species | Expression System |
---|---|---|---|
TMPY-02495 | P19 INK4d Protein, Human, Recombinant (GST) | Human | E. coli |
Cyclin-dependent kinase inhibitor 2D(also known as CDKN2D or p19ink4d), a member of the INK4 family of cyclin-dependent kinase (CDK) inhibitors, negatively regulates the cyclin D-CDK4/6 complexes, which promote G1/S tran... | |||
TMPY-04542 | CDK2 Protein, Human, Recombinant (His) | Human | Baculovirus Insect Cells |
CDK2 is a member of the Ser/Thr protein kinase family. This protein kinase is highly similar to the gene products of S. cerevisiae cdc28, and S. pombe cdc2. It is a catalytic subunit of the cyclin-dependent protein kinas... | |||
TMPJ-00827 | Tau-D Protein, Human, Recombinant (His) | Human | E. coli |
Microtubule-Associated Protein TAU is abundantly expressed in neurons of the central nervous system and less commonly expressed elsewhere, but is also expressed at very low levels in CNS astrocytes and oligodendrocytes. ... | |||
TMPK-00614 | NKp46/NCR1 Protein, Human, Recombinant (His) | Human | HEK293 Cells |
NKp46, along with NKp30 and NKp44, are activating receptors that have been collectively termed the natural cytotoxicity receptors (NCR).These receptors lack significant sequence homology to one another. They are expresse... | |||
TMPY-04277 | CD45 Protein, Mouse, Recombinant (hFc) | Mouse | HEK293 Cells |
CD45 Protein, Mouse, Recombinant (hFc) is expressed in HEK293 mammalian cells with hFc tag. The predicted molecular weight is 71.7 kDa and the accession number is P06800-6. | |||
TMPY-03010 | NRG1 beta 1 Protein, Human, Recombinant | Human | HEK293 Cells |
NRG1 beta 1 Protein, Human, Recombinant is expressed in HEK293 mammalian cells. The predicted molecular weight is 26.8 kDa and the accession number is Q02297-6. | |||
TMPY-02705 | NRG1 beta 1 Protein, Human, Recombinant (hFc) | Human | HEK293 Cells |
NRG1 beta 1 Protein, Human, Recombinant (hFc) is expressed in HEK293 mammalian cells with Fc tag. The predicted molecular weight is 55.2 kDa and the accession number is Q02297-6. | |||
TMPJ-00567 | NCR1 Protein, Human, Recombinant (hFc) | Human | HEK293 Cells |
Natural cytotoxicity triggering receptor 1(NCR1) is a single-pass type I membrane protein .It contains 2 Ig-like (immunoglobulin-like) domains and belongs to the natural cytotoxicity receptor (NCR) family. The protein is... | |||
TMPY-02600 | NRG1 beta 1 Protein, Human, Recombinant (EGF Domain, hFc) | Human | HEK293 Cells |
NRG1 beta 1 Protein, Human, Recombinant (EGF Domain, hFc) is expressed in HEK293 mammalian cells with Fc tag. The predicted molecular weight is 36.7 kDa and the accession number is Q02297-6. | |||
TMPY-05798 | VEGF145 Protein, Human, Recombinant | Human | HEK293 Cells |
VEGF145 Protein, Human, Recombinant is expressed in HEK293 mammalian cells. The predicted molecular weight is 16.92 kDa and the accession number is P15692-6. | |||
TMPY-03128 | LAIR1 Protein, Mouse, Recombinant (hFc) | Mouse | HEK293 Cells |
LAIR1 Protein, Mouse, Recombinant (hFc) is expressed in HEK293 mammalian cells with hFc tag. The predicted molecular weight is 39.6 kDa and the accession number is Q8BG84-6. | |||
TMPK-00615 | NKp46/NCR1 Protein (Primary Amine Labeling), Human, Recombinant (His), Biotinylated | Human | HEK293 Cells |
NKp46, along with NKp30 and NKp44, are activating receptors that have been collectively termed the natural cytotoxicity receptors (NCR).These receptors lack significant sequence homology to one another. They are expresse... | |||
TMPK-01364 | SIRP alpha V6 Protein, Human, Recombinant (His & Avi), Biotinylated | Human | HEK293 Cells |
Signal regulatory protein α (SIRPα) is a regulatory membrane glycoprotein from SIRP family expressed mainly by myeloid cells and also by stem cells or neurons.SIRPα acts as inhibitory receptor and interacts with a broadl... | |||
TMPK-01358 | SIRP alpha V6 Protein, Human, Recombinant (His & Avi) | Human | HEK293 Cells |
Signal regulatory protein α (SIRPα) is a regulatory membrane glycoprotein from SIRP family expressed mainly by myeloid cells and also by stem cells or neurons.SIRPα acts as inhibitory receptor and interacts with a broadl... |
カタログ番号 | 製品名 | ||
---|---|---|---|
L2191 | Anti-Breast Cancer Compound Library | 1939 compounds | |
A unique collection of 1939 compounds with anti-breast cancer therapeutic activity or targeting breast cancer’s major signaling pathways, can be used for anti-breast cancer drug discovery and mechanism study; |